Ultragenyx Pharmaceutical (RARE) Change in Receivables (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Change in Receivables data on file, last reported at -$19.0 million in Q1 2026.

• On a quarterly basis, Change in Receivables fell 90.0% year-over-year to -$19.0 million in Q1 2026; TTM through Mar 2026 was $22.0 million, a 2522.91% increase from a year earlier, with the FY2025 full-year figure at $31.0 million, down 8.82% from the prior year.
• Change in Receivables for Q1 2026 stood at -$19.0 million, down from $33.8 million in the prior quarter.
• Over the last five years, Change in Receivables for RARE reached as high as $33.8 million in Q4 2025 and fell as low as -$19.0 million in Q1 2026.
• Historically, Change in Receivables has averaged $4.8 million across 5 years, with a median of $2.5 million in 2023.
• Across the five-year window, Change in Receivables tumbled 955.56% in 2022 and jumped 7700.0% in 2023, its largest moves.
• Year by year, Change in Receivables stood at $9.1 million in 2022, then slumped by 108.69% to -$790000.0 in 2023, then surged by 2763.54% to $21.0 million in 2024, then jumped by 60.79% to $33.8 million in 2025, then sank by 156.16% to -$19.0 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were -$19.0 million in Q1 2026, $33.8 million in Q4 2025, and -$5.4 million in Q3 2025.